Hans Kupper
Partner @ Global Life Science Ventures
München, Germany
Hans Kupper is a Series A investor at Global Life Science Ventures in München focused on Health Care and Biotechnology. Dr. Hans Kupper is a partner at Global Life Science Ventures since 1999. Dr Kupper has 29 years of experience in biotechnology with 19 years in the life science industry, where he has been involved in activities from R&D and R&D management to technology assessment and acquisitions.In 1980, Dr. Kupper joined Biogen where he held variousR&D and management positions, including Assistant Research Director.In 1985, he joined Behringwerke AG to build and head the Molecular Biology Department and later became head of R&D at the Immunology/Oncology business unit.Since 1991, Dr Kupper has been increasingly involved in deal negotiations, acquisitions, joint ventures, and lead the spin-off of the vaccine unit and the diagnostics business of Behringwerke AG.Dr Kupper earned a PhD from the University of Heidelberg and was a postdoctoral fellow at MIT in Boston with Nobel Laureate Prof. Khorana.Dr. Kupper is a member on several Boards of Directors including Chairman of the Board of Pieris, board member of Action Pharma, IMI Intelligent Medical Implants, and an observer of the board of 7TM.Dr. Kupper was first elected to the Board of Santaris Pharma A/S in 2010.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Hans Kupper invests in
Stages Hans Kupper invests in
Countries Hans Kupper invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Pharmaceutical 2 (67%)
- Medical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Series C 1 (33%)
Country
- Denmark 1 (33%)
- Germany 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Action Pharma
|
Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark. | $6.3M / Series C / Jul 16, 2010 | |
Pieris
|
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $6.4M / Series B / Nov 01, 2006 | |
|
Pieris
|
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $13.2M / Series A / Oct 31, 2002 |
Co-Investors
Global Life Science Ventures (GLSV) was a venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance,advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.
Global Life Science Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hans Kupper
Partner
|
|||
|
Bert van Toor
Investment Manager
|
|||
Peter Reinisch
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hans Kupper invest in?
Hans Kupper invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hans Kupper?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Hans Kupper last invest?
The most recent investment recorded for Hans Kupper closed in Jul 2010. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
